Paclitaxel
Chemotherapeutic Drug
Cramer's Mad Money - Agnico Eagle's Golden Disappointment (11/2/09)...patent in 2012. Currently Bristol Myers has a Phase III drug for metastic melanoma, Erbitux for colorectal, head and neck cancer, Sprycel for Leukemia, Ixempra for breast cancer and Taxol for breast, lung and ovarian cancer. Sprycel is the... In this article: Jim Cramer, Pfizer, Bristol Myers, Jarden, Stanley Works, Black & Decker, BHP, 3M, Cancer, and Agnico Eagle Mines |
-
The Seattle Times | December 12, 2008
Bristol-Myers, biotech Exelixis team up on cancer
...drug Erbitux through a partnership with ImClone Systems Inc. The company also makes leukemia treatment Sprycel, breast cancer drug Ixempra and the chemotherapy agent Taxol. Bristol-Myers has three other cancer drugs in late-stage...
In this article: Bristol-Myers, Cancer, Revenue, ImClone Systems Inc., Ixempra, Sprycel, Leukemia, Erbitux, and Breast cancer
-
Medical News Today | April 20, 2009
Enhanced Effect Achieved In Certain Ovarian Cancers By Addition Of Dasatinib To Standard Chemo Cocktail
...in some ovarian cancers, she said. Currently a phase I trial of a combination of dasatinib, paclitaxel and carboplatin is available for women with advanced or recurrent ovarian, tubal and peritoneal cancers. Dasatinib is a chemotherapeutic...
In this article: Dasatinib, Cancer, Ovarian cancer, Carboplatin, Leukemia, Bristol-Myers Squibb, FDA, and Medical advice
-
MedicineNet | April 20, 2009
Chemo Combo Shows Promise Against Ovarian Cancer
"By examining gene expression data, we determined that the combination of the leukemia drug dasatinib (Sprycel) made carboplatin and paclitaxel more effective in cell lines with higher levels of SRC expression and SRC pathway...
In this article: Dasatinib, Ovarian cancer, Carboplatin, Cancer, Leukemia, Targeted therapy, and American Association for Cancer Research
-
en.wikipedia.org
Paclitaxel - Wikipedia, the free encyclopedia
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. ... protein called Bcl-2 (B-cell leukemia 2) and thus arresting its function. ...
-
www.cancer.gov
Clinical Trials (PDQ®) - National Cancer Institute
Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or ... paclitaxel given as a 96-hour infusion in patients with acute leukemia ...
-
clinicaltrials.gov
Paclitaxel in Treating Patients With Refractory or Recurrent ...
Paclitaxel in Treating Patients With Refractory or Recurrent Acute Leukemia or ... Paclitaxel. Therapeutic Uses. Tubulin Modulators. Leukemia, Myelogenous, ...
-
bloodjournal.hematologylibrary.org
Blood -- Induction of tumor necrosis factor by bryostatin 1 ...
... leukemia cells (U937) and in highly paclitaxel-resistant cells ectopically ... Bryostatin 1 potentiates paclitaxel-induced apoptosis in human leukemia cells ...
-
Chemotherapy Given With Amifostine and Filgrastim in Treating ...
Leukemia. Lymphoma. Unspecified Adult Solid Tumor, Protocol Specific. Biological: filgrastim ... OUTLINE: This is a dose escalation study of paclitaxel. ...
-
Definition of DHA-paclitaxel - National Cancer Institute Drug ...
... the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). DHA-paclitaxel exhibits improved pharmacokinetic and toxicity profiles when ...
Trends
Loading...
More on Paclitaxel
Description from Wikipedia:
-1,9- dihydroxy-10,14,17,17-tetramethyl -11-oxo-6-oxatetracyclo [11.3.1.0~3,10~.0~4,7~] heptadec-13-en-2-yl benzoate
| image = Taxol.svg
| width = 350
| CAS_number = 33069-62-4
| ChemSpiderID = 10368587
| ATC_prefix = L01
| ATC_suffix = CD01
| PubChem = 36314
| DrugBank = APRD00259
| C=47 | H=51 | N=1 | O=14
| molecular_weight = 853.906 g/mol
| bioavailability = 6.5% (oral)
| protein_bound = 89 to 98%
| metabolism = Hepatic (CYP2C8 and CYP3A4)
| elimination_half-life = 5.8 hours
| excretion = Fecal and urinary
| pregnancy_AU =
| pregnancy_US = D
| pregnancy_category =
| legal_status = Rx-=only
| routes_of_administration = iv
}}
Paclitaxel is a mitotic inhibitor used in cancer chemotherapy. It was discovered in a National Cancer Institute program at the Research Triangle Institute in 1967 when Monroe E. Wall and Mansukh C. Wani isolated it from the bark of the Pacific yew tree, Taxus brevifolia and named it 'taxol'. When it was developed commercially by Bristol-Myers Squibb (BMS) the generic name was changed to 'paclitaxel' and the BMS compound is sold under the trademark 'Taxol'. In this formulation paclitaxel is dissolved in Cremophor EL and ethanol, as a delivery agent. A newer formulation, in which paclitaxel is bound to albumin, is sold under the trademark Abraxane.
Paclitaxel is now used to treat patients with lung, ovarian, breast cancer, head and neck cancer, and advanced forms of Kaposi's sarcoma. Paclitaxel is also used for the prevention of restenosis.
Paclitaxel works by interfering with normal microtubule breakdown during cell division. Together with docetaxel, it forms the drug category of the taxanes. It was the subject of a notable total synthesis by Robert A. Holton.
Explore everything named Paclitaxel...
